When used in combination with a sulfonamide and leucovorin, Daraprim is the preferred treatment among infectious disease specialists for toxoplasmosis. The drug was acquired from Impax Laboratories, Inc...

By

LeafBio, Inc. (LeafBio), the commercial arm of Mapp Biopharmaceutical, Inc. (Mapp), announced last week that the U.S. Food and Drug Administration (FDA) has granted ZMapp™ “Fast Track” designation...

By

Merck has announced that the two pivotal Phase 3 clinical studies for bezlotoxumab, its investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence, met their...

By

The U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation to VT-1129, a novel candidate for the treatment of cryptococcal meningitis, according to...

By

Researchers at two prominent facilities continue the quest for newer and better treatment options for the drug resistant strain of Staphylococcus aureus (MRSA). Researchers at Washington University School...

By

The Drugs for Neglected Diseases initiative (DNDi) has announced today at the 9th European Congress on Tropical Medicine and International Health (ECTMIH) in Basel, Switzerland, the successful completion...

By

Garcinia cambogia is an extremely popular “weight-loss” supplement in the US thanks in part to Dr. Oz, so much that one million Americans a month “google” the product. According...

By

Novel drug candidate, MRX-I, an oral oxazolidinone showed positive top-line results from the first Phase 2 clinical study in China, according to biopharmaceutical company, MicuRx Pharmaceuticals,...

By

The One Minute Miracle Inc. is voluntarily recalling one lot each of Miracle Diet 30, capsules and Miracle Rock 48. Miracle Diet 30 has been found to contain undeclared phenolphthalein, phenolphthalein...

By

The U.S. Food and Drug Administration today approved Repatha (evolocumab) injection for some patients who are unable to get their low-density lipoprotein (LDL) cholesterol under control with current treatment...